Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02502903

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders — BIVV009-01  

End-stage Renal Disease (ESRD) Clinical Trial

Official title:
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.

Clinical Trial Summary

Prospective, double-blind, randomized, placebo-controlled First-In-Human study with four sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in NHVs, Part C, a multiple dose (MD) study in patients with a complement-mediated disorder, and Part E, a multiple dose (MD) study in patients with cold agglutinin disease previously treated with BIVV009 within the scope of a BIVV009 clinical trial or named patient program use. Note: For parts A-C as well as at the start of part E, study drug was named TNT009. The study drug name is changed to BIVV009 with final version Final 15.0 of the clinical study protocol.

Clinical Trial Description

Study TNT009-01 (parts A-C)/ BIVV009 (part E) is a First in Human (FIH) study that uses an Integrated Protocol Design. This Phase 1 study protocol will comprise three sub-parts: a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study in normal male and female human volunteers (NHVs), and a Multiple Dose (MD) study in patients with various complement-mediated disorders not confined to a single disease or therapeutic area. Although these patients represent a population with a diverse set of clinical diagnoses they are united by a common mechanism of disease matched to the mechanism of action of BIV009. Several key safety measures have been incorporated into the design of this study, including use of Sentinel Dosing Groups and an independent Data Safety Monitoring Board (DSMB), as well as an appropriate program of prophylactic vaccinations and clinical biomarker surveillance related to the risks potentially associated with inhibition of the complement system. To allow access of BIVV009 to CAD patients where successful treatment effect has been observed and to allow re-initiation of BIVV009 to previously treated CAD patients, Part E has been added to both continued access to study drug in this subset of study patients, and to further characterize the safety and efficacy to BIVV009. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02502903
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 1
Start date July 13, 2015
Completion date March 31, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02553889 - A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis Phase 2
Completed NCT01222234 - Impact of Vitamin D Therapies on Chronic Kidney Disease N/A
Recruiting NCT00243958 - Aluminum and Auditory Function in ESRD N/A
Active, not recruiting NCT03989141 - Creating a Buttonhole Tunnel Track by Repeated Needling of the AV Fistula on the Same Day in Patients on Hemodialysis. N/A
Completed NCT01526798 - Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis N/A
Completed NCT05285787 - A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD) Phase 2
Completed NCT05769595 - Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012) Phase 1
Completed NCT03119818 - Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy N/A
Not yet recruiting NCT06468826 - A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD) Phase 1
Completed NCT01228279 - Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis Phase 4
Enrolling by invitation NCT06243900 - NIRS for the Diagnosis of Residual Renal Function Injury in Hemodialysis Patients
Completed NCT03358030 - A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis Phase 2
Recruiting NCT01415570 - Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD) N/A
Completed NCT00548249 - Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis Phase 2